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Abstract
Myotonic dystrophy type 2 (DM2) is a genetic, autosomal dominant disease due to expansion of tetraplet (CCTG) repetitions
in the first intron of the ZNF9/CNBP gene. DM2 is a multisystemic disorder affecting the skeletal muscle, the heart, the eye
and the endocrine system. According to the proposed pathological mechanism, the expanded tetraplets have an RNA toxic
effect, disrupting the splicing of many mRNAs. Thus, the identification of aberrantly spliced transcripts is instrumental for
our understanding of the molecular mechanisms underpinning the disease. The aim of this study was the identification of
new aberrant alternative splicing events in DM2 patients. By genome wide analysis of 10 DM2 patients and 10 controls
(CTR), we identified 273 alternative spliced exons in 218 genes. While many aberrant splicing events were already identified
in the past, most were new. A subset of these events was validated by qPCR assays in 19 DM2 and 15 CTR subjects. To gain
insight into the molecular pathways involving the identified aberrantly spliced genes, we performed a bioinformatics
analysis with Ingenuity system. This analysis indicated a deregulation of development, cell survival, metabolism, calcium
signaling and contractility. In conclusion, our genome wide analysis provided a database of aberrant splicing events in the
skeletal muscle of DM2 patients. The affected genes are involved in numerous pathways and networks important for muscle
physio-pathology, suggesting that the identified variants may contribute to DM2 pathogenesis.
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Introduction
Myotonic dystrophies are dominantly inherited multisystemic
disorders characterized by muscle weakness, myotonia, CNS
involvement and cataracts.
Two types of DM have been described. Myotonic dystrophy
type 1 (DM1) or Steinert’s disease (DM1, OMIM 160900) is one of
the most common forms of muscular dystrophy in adults with a
prevalence of 1/8000 worldwide [1]. It is caused by an expanded
(CTG)n repeat in the 3’ untranslated region of the Dystrophia
Myotonica Protein Kinase (DMPK) gene [2–4].
Myotonic dystrophy type 2 (DM2, OMIM 602688) displays a
prevalently proximal impairment and milder clinical symptoms
than DM1. It is caused by the expansion of a tetranucleotidic
repetition (CCTG)n in the first intron of the CCHC-type zinc finger,
nucleic acid binding protein (CNBP) gene [5].
The disease mechanism proposed for both DM types involves a
toxic gain-of-function by RNA: the mutation causes the accumu-
lation of the expanded CUG/CCUG transcripts into nuclear
RNA foci [6], which sequester RNA-binding proteins, such as
MBNL1 (Muscleblind-like 1) that decreases its activity in DM
patients [7], while the amount of CELF1 (CUGBP/Elav-like
family member 1) increases [8–10]. These events lead to the
expression of aberrant embryonic protein isoforms in adult tissues,
muscular as well as other [11]. Thus, the pervasive spliceopathy
observed in DM is indicated as a likely cause of the multisystemic
features of this disease [12].
Alternative splicing (AS) is a post-transcriptional event whereby
exons are joined by different combinations generating various
isoforms from a single gene. It has been shown that most genes
have at least 2 alternative isoforms [13,14]. The expression of AS-
generated isoforms can be tissue-, development- or sex-specific and
these isoforms can fulfill different or even opposing functions [14–
16]. Several studies investigated a limited number of genes
aberrantly spliced in DM1, DM2 or both [17–26], but so far, only
few studies investigated genome-wide changes in splicing events in
DM1 and DM2 patients: one was limited to muscle specific genes
[21]; another recent investigation profiled both DM1 and DM2
patients, but the validation phase was restricted to DM1 patients
[27] and a third one admittedly displayed relatively low sensitivity
[28]. Given the high variability of DM patients and the limited
number of patients that is feasible to recruit, due to the rarity of
the disease, it is clear that more insight on the AS aberrations in
DM2 skeletal muscles is needed.
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The GeneChip Human Exon 1.0 ST Array investigates the
expression of virtually all known and many predicted human
exons (,1 million) allowing genome-wide evaluation of splicing
events. Therefore, we used the exon array technology to explore
DM2-related alternative splicing in muscle biopsies. We identified
more than 200 genes displaying aberrant AS in DM2, likely
affecting DM2-deregulated pathways and networks.
Materials and Methods
Patients selection and skeletal muscle biopsies
This study was authorized by the Institutional Ethics Commit-
tee (Azienda Sanitaria Locale-Milano 2) and was conducted
according to the principles expressed in the Declaration of
Helsinki, the institutional regulations and Italian laws and
guidelines. All biopsy specimens were taken after specific written
informed consent was obtained. Human muscle biopsies from
biceps brachii were harvested under sterile conditions and snap-
frozen in liquid nitrogen. Clinical diagnosis of DM2 was based
upon the criteria set by the International Consortium for
Myotonic Dystrophies [29]. Fluorescence in situ hybridization
was performed on frozen muscle sections to confirm DM2
diagnosis according to Cardani et al. [30]. Control (CTR) biopsies
were from subjects admitted with suspected neuromuscular
disorder of undetermined nature. CTR biopsies did not show
overt signs of muscle pathology upon on histological and
immunohistochemical examination. All muscle biopsies were
processed by the same pathology team and each was analyzed
by two expert pathologists.
Sample preparation and data analysis.
Total RNA was extracted using TRIzol (Invitrogen) and the
TissueLyser system (Qiagen) and gene expression profiles were
measured using the Gene Chip Human Exon 1.0 ST Array
(Affymetrix) as previously described [31]. CEL files (GEO dataset
GSE37794) with raw data were uploaded to the Exon Array
Analyzer (EAA) 2.2 server (http://eaa.mpi-bn.mpg.de/) [32].
EAA first executed the Affymetrix Power Tools (APT) (http://
www.affymetrix.com) for background correction, normalization
and summarization of raw signals (Fig.1). These software
implemented Iter-PLIER and RMA (Affymetrix Inc., 2005) for
exon and gene-level processing, respectively, as well as the
Detection Above Background (DABG) method. Exon-level data
were filtered to include only those probe sets that were included
within the ‘‘Core Meta-Probeset’’, composed by 17,800 transcript
clusters of RefSeq and full-length GenBank mRNAs (Release
March 2006-NCBI36/hg18). To reduce false positives, the
following transcripts/probe sets were discarded: 1) probe sets that
were not expressed in at least one group (DABG p-value .0.05 in
.50% of the samples); 2) transcript clusters that were not
expressed in both groups (.50% of their probe sets not detected in
.50% of samples); 3) probe sets with high potential for cross
hybridization, i.e. probe sets with only one hybridization probe
positive; 4) genes with very large expression differences ($10-fold
difference); 5) probe sets with very large gene-level normalized
intensities ($5) [32,33] (http://eaa.mpi-bn.mpg.de/;http://www.
affymetrix.com/support/technical/technotes/id_altsplicingevents_
technote.pdf).
Gene-level normalized intensities (NI) and the Splice Index (SI)
[34] were calculated as indicated below.
Gene Level Normalized Intensity NIð Þ~Probe set intenisty=
Expression level of the gene
Splice Index SIð Þ~log2 (DM2 NI=CTR NI)
The R/Bioconductor [35], package LIMMA [36] was used for
differential analysis; the Student’s t-test of gene-level normalized
intensities was calculated and corrected for multiple comparison
[37]. The Splice Index, gene level normalized intensities and p-
values were imported into MySQL tables, which were used by the
web interface to display results and generate graphics.
Reverse transcription PCR validation
mRNA levels were measured using the SYBR-GREEN
quantitative PCR (qPCR) method (Life Technologies) as previ-
ously reported [31] using a 7900HT Fast Real Time PCR System
(Applied Biosystems). cDNAs were amplified using specific primers
indicated in Table S1; data results were normalized against
RPL13 and relative expression was calculated using the compar-
Figure 1. Array analysis workflow for AS identification. The
scanning of hybridized GeneChip Human Exon 1.0 ST Affymetrix
microarrays, after quality control, generated raw CEL files. These were
uploaded on Exon Array Analyzer and processed by Affymetrix Power
Tools (APT). Iter-PLIER and RMA performed a data pre-processing, while
DABG calculated p-values to indicate if the exon signal was detected
within or above the background noise. Next gene expression, gene
level normalized exon expression, splicing index were calculated. Only
events with a p value,0.05 and a splicing index ,-0.5 or .+0.5 were
considered. Next, 5 further selection criteria were applied in order to
minimize the number of false positives (see Methods). This analysis
yielded 273 alternative spliced exons in DM2 patients.
doi:10.1371/journal.pone.0093983.g001
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ative Ct method 2{DDCt [38]. Each sample was measured in
triplicate and values were averaged. For the CaMK2G gene,
reverse transcription PCR products were also resolved onto a 5%
polyacrylamide electrophoresis gel, stained with ethidium bromide
for UV visualization, and the extracted bands, which represent the
two different isoforms, were verified by DNA sequencing.
Bioinformatic analysis of pathways and functions
Pathway analysis was performed using Ingenuity Pathways
Knowledge Base-v8.8 (Ingenuity Systems, content version
17199142, release date 17/09/2013) using Genes with LIMMA
adjusted p-value ,0.05 and -0.5.S.I. 0.5 as reference set and
assuming direct and indirect relationships. Fisher’s exact test p-
value,0.05 was deemed as statistically significant.
For network analysis, first, we built Metacore Networks
(Analyze Networks algorithm, v6.13 build 43450, GeneGO,
Thomson Reuters) using DMPK gene and Myotonic Dystrophy
related genes as inputs for the algorithm (ACE, ATXN1,
CDC42BPB, CNBP, CELF1, CAPNS1, DMPK, DMWD,
DMD, INSR, CDC42BPA, FXYD1, TNFRSF1B, TNF,
TSPAN7, TNF, TNFRSF1B) and looked for genes in our dataset
that intersected the top-score sub-networks related to DM. Next,
we created a core network of direct interactions amongst our
LIMMA significant genes; we also expanded the network by
adding genes outside our dataset, whose interaction is curated in
MetaCore. We identified smaller network communities that were
prioritized by number of genes in our dataset. We used this second
approach to analyze our data set without any prior knowledge.
Statistical analysis
Continuous variables are expressed as mean6standard error
(SE), unless indicated differently. For group-wise comparisons,
Mann–Whitney test or t-test were used as appropriate. All tests
were performed 2-sided and a p,0.05 was considered as
statistically significant.
Results
Global AS analysis by exon arrays.
In a previous work [31], we analyzed gene expression
differences in biceps brachii muscle biopsies of 10 DM2 and 10
control age and sex matched subjects (Table S2) using GeneChip
Human Exon 1.0 ST Arrays. In this follow-up investigation, the
same dataset was used to investigate AS events in genes exhibiting
no difference in expression (Fig. 1). The Exon Array Analyzer
(EAA) software analysis predicted 273 AS events distributed on
218 genes, with SI .+0.5 or ,-0.5 and p-value ,0.05 (Table S3).
In particular, 164 splicing events had a positive SI and were
classified as exon inclusions (SI.+0.5), while 54 had a negative SI
and were exon deletions (SI,-0.5). Interestingly, 46 AS splicing
events were already annotated in AStalavista (http://genome.crg.
es/astalavista/) or in the UCSC Genome Browser (http://
genome.ucsc.edu/), albeit most of them not in this specific disease
context: 27 were cassette exons (both exon inclusion or exclusion),
6 were intron retentions, 10 were bleeding exons (initial or
terminal exons overlap with an intron), while 3 events were not
classified as AS, but as alternative promoter usage [39].
Comparison with previous studies and qPCR validation.
Numerous AS events identified by our screening had previously
described as deregulated either in DM1 or DM2 or both (Table
S4). For instance, as previously reported [17], the EAA software
analysis identified MBNL1 (Muscleblind-like splicing regulator 1)
exon 7 inclusion (Fig. S1) and FHOD1 (Formin HOmology 2
Domain containing 1) exon 11 inclusion (Fig. S2) events as more
frequent in DM2 patients compared to controls. Furthermore, in
keeping with previous data [21,26], LDB3 (LIM Domain Binding
3, Fig. S3) and NFIX (Nuclear Factor I/X, Fig. S4) exhibited
inclusion of exon 4 and exon 7, respectively, in DM2 patients. The
preferential skipping in DM2 patients of exon 6 of MAPT/TAU
(Microtubule-associated Protein Tau) was also confirmed (Fig. S5)
[27,40].
Finally, a very recent global analysis identified aberrant AS
events in DM1 and DM2 [27]. Among those validated by reverse
transcription PCR in a DM1 group, EAA software identified 28
AS events that were similarly deregulated in our DM2 cohort.
Chi-square test confirmed that this overlap was statistically
significant (p,0.001).
In order to further corroborate our analysis, we validated a
subset of AS events by qPCR. To this aim, we used biceps brachii
biopsies derived from 19 DM2 and 15 CTR age and sex matched
patients. Of note, only 4 DM2 and 6 control individuals were in
common between the screening and the validation cohorts (Tab
S2 and S5).
In keeping with previous reports [27,41], EAA indicated that
PDLIM3 (PDZ and LIM domain 3) (Fig.2A–B) and PHKA1
[phosphorylase kinase, alpha 1 (muscle)] (Fig.3 A–B) both
displayed an exon cassette inclusion event in DM2 patients. We
designed primers specific for exon 4 of PDLIM3 and exon 19 of
PHKA1 (Tab. S1) and amplified the cDNAs. As expected, we
found increased exon inclusion in DM2 patients for both genes
(Fig. 2C and 3C).
Likewise, two other genes among those described in both DM1
and DM2 [27,41] were identified by EAA, LIMCH1 (LIM and
calponin homology domains 1) and NDUFV3 (NADH Dehydro-
genase (Ubiquinone) Flavoprotein 3), that both showed a exon
cassette skipping event in DM2 compared to CTR. Specifically,
exon 10 and 11 of LIMCH1 were predicted as significantly mis-
spliced by EAA results (Fig.4). qPCR experiments confirmed the
more frequent inclusion of exon 10. However, differences in exon
11 inclusion in DM2 patients did not reach statistical significance
(Fig.4E). In the case of NDUFV3, EAA outputs showed exon 3
skipping in DM2 patients compared to CTR (Fig. 5A and B); these
data were confirmed by qPCR using a exon 3-specific primer pair
(Fig. 5C).
Nakamori et al. identified in DM1 patients the retention of 18–
19 intron in CAMK2G (calcium/calmodulin-dependent protein
kinase II gamma) transcript [27,41]. EAA analysis of our data did
not detect this event, but indicated that exon 18 of CAMK2G was
more frequently retained in DM2 compared to CTR samples
(Fig.6B). This result was confirmed by qPCR using a primer pair
spanning from exon 17 to exon 18 (Fig.6C). Moreover, using
primers spanning from exon 16 to exon 19, the obtained amplicon
was resolved on 5% PAGE (Fig.6D). As expected, both DM2 and
CTR displayed a 160 bp amplicon corresponding to the transcript
skipping exon 18. However, DM2 patients also showed a 248 bp
amplicon associated to an exon 18-including transcript. The
identity of the amplicons and the fidelity of the exon 17/18 and
18/19 junctions were confirmed by DNA sequencing.
Next, we extended our analysis to other AS events not
previously associated to DM1 or DM2, testing a variety of AS
events.
EAA results indicated that ZMYND11 (zinc finger, MYND-
type containing 11) (Fig. 7 A and B), PDP1 (pyruvate
dehyrogenase phosphatase catalytic subunit 1) (Fig. 8 A and B)
and ERI2 (ERI1 exoribonuclease family member 2) (Fig. 9 A and
B) displayed an exon cassette inclusion event, while VCL (vinculin)
(Fig. 10 A and B) displayed and exon cassette skipping event. We
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designed primers specific for exon 2 of ZMYND11, exon 2 of
PDP1, exon 16 of ERI2 and exon 19 of VCL (Tab S1) and
amplified the cDNAs. qPCR confirmed all predicted AS events
(Figs. 8C, 9C and 10 C).
Moreover, EAA indicated that MBOAT7 (Membrane Bound
O-AcylTransferase domain containing 7) (Fig. 11 A–B), DNMT3L
(DNMT3L DNA (cytosine-5-)-methyltransferase 3-like) (Fig. 12 A–
B) and LAMC2 (laminin, gamma 2) (fig.13 A–B) displayed
Figure 2. Increased PDLIM3 exon 4 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 4 of PDLIM3 mRNA transcript
ENST00000284767. The AS area is enlarged and exon 4, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 2796971 recognizing exon 4, in DM2 patients compared to CTR (n = 10, **** p,0.0001). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; *** p,0.001).
doi:10.1371/journal.pone.0093983.g002
Figure 3. Increased PHKA1 exon 19 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 19 of PHKA1 mRNA transcript
ENST00000339490. The AS area is enlarged and exon 19, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 4012322 recognizing exon 19, in DM2 patients compared to CTR (n = 10, **** p,0.0001). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; ** p,0.01).
doi:10.1371/journal.pone.0093983.g003
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Figure 4. Increased LIMCH1 exon 11 skipping in DM2 patients. A) EAA analysis identified an AS event on exons 11 and 12 of LIMCH1 mRNA
transcript ENST00000313875. The AS area is enlarged and exons 11 and 12, less frequently included in DM2 patients, are highlighted in solid gray. B
and D) The box plots show the decreased expression of Affymetrix probe set 2725148 recognizing exon 11 (B) and 2725151 recognizing exon 12 (D),
in DM2 patients compared to CTR (n = 10, **** p,0.0001). Values are normalized for the levels of the whole transcript. The splice index (SI) is
indicated. C and E) Validation qPCR assays were performed using the specific primer pairs indicated as black arrowhead in panel A. Results are shown
as fold change (DM2=19, CTR = 15; ** p,0.01). Only LIMCH1 exon 11 skipping was validated.
doi:10.1371/journal.pone.0093983.g004
Figure 5. Increased NDUFV3 exon 3 skipping in DM2 patients. A) EAA analysis identified an AS event on exon 3 of NDUFV3 mRNA transcript
ENST00000354250. The AS area is enlarged and exon 3, less frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the decreased expression of Affymetrix probe set 3922937 recognizing exon 3, in DM2 patients compared to CTR (n = 10, **** p,0.0001). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; ** p,0.01).
doi:10.1371/journal.pone.0093983.g005
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Figure 6. Increased CAMK2G exon 18 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 18 of CAMK2G mRNA
transcript ENST00000394763. The AS area is enlarged and exon 18, more frequently included in DM2 patients, is highlighted in solid gray. B) The box
plot shows the increased expression of Affymetrix probe set 3294875 recognizing exon 18, in DM2 patients compared to CTR (n = 10, **** p,0.0001).
Values are normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the
specific primer pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR = 15; **** p,0.0001). D) Reverse
transcription PCR products obtained with the specific primer pair indicated as black lines in panel A, were resolved on 5% polyacrylamide
electrophoresis gel. The 250 bp fragment containing exon 18 was more abundant in DM2 patients.
doi:10.1371/journal.pone.0093983.g006
Figure 7. Increased ZMND11 exon 2 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 2 of ZMND11 mRNA transcript
ENST00000381584. The AS area is enlarged and exon 2, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 3231406 recognizing exon 2, in DM2 patients compared to CTR (n = 10, * p,0.05). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; * p,0.05).
doi:10.1371/journal.pone.0093983.g007
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Figure 8. Increased PDP1 exon 2 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 2 of PDP1 mRNA transcript
ENST00000396200. The AS area is enlarged and exon 2, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 3107346 recognizing exon 2, in DM2 patients compared to CTR (n = 10, **** p,0.0001). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; ** p,0.01).
doi:10.1371/journal.pone.0093983.g008
Figure 9. Increased ERI2 exon 16 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 16 of ERI2 mRNA transcript
ENST00000261377. The AS area is enlarged and exon 16, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 3651550 recognizing exon 16, in DM2 patients compared to CTR (n = 10, ** p,0.01). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; ** p,0.01).
doi:10.1371/journal.pone.0093983.g009
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Figure 10. Increased VCL exon 19 skipping in DM2 patients. A) EAA analysis identified an AS event on exon 19 of VCL mRNA transcript
ENST00000211998. The AS area is enlarged and exon 19, more frequently excluded in DM2 patients, is highlighted in solid gray. B) The box plot
shows the decreased expression of Affymetrix probe set 3252129 recognizing exon 19, in DM2 patients compared to CTR (n = 10, **** p,0.0001).
Values are normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the
specific primer pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; * p,0.05).
doi:10.1371/journal.pone.0093983.g010
Figure 11. Increased MBOAT7 exon 8 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 8 of MBOAT7 mRNA
transcript ENST00000245615. The AS area is enlarged and exon 8, more frequently included in DM2 patients, is highlighted in solid gray. B) The box
plot shows the increased expression of Affymetrix probe set 3870571, recognizing exon 8 in DM2 patients compared to CTR (n = 10; **** p,0.0001).
Values were normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the
specific primer pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; *** p,0.001).
doi:10.1371/journal.pone.0093983.g011
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Figure 12. Increased DNMT3L exon 12 skipping in DM2 patients. A) EAA analysis identified an AS event on exon 12 of DNMT3L mRNA
transcript ENST00000418993. The AS area is enlarged and exon 12, more frequently excluded in DM2 patients, is highlighted in solid gray. B) The box
plot shows the decreased expression of Affymetrix probe set 3934442 recognizing exon 12, in DM2 patients compared to CTR (n = 10, ** p,0.01).
Values are normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the
specific primer pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; ** p,0.01).
doi:10.1371/journal.pone.0093983.g012
Figure 13. Increased LAMC2 exon 23 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 23 of LAMC2 mRNA transcript
ENST00000264144. The AS area is enlarged and exon 23, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 2371184, recognizing exon 23, in DM2 patients compared to CTR (n = 10, * p,0.05). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; *p,0.05).
doi:10.1371/journal.pone.0093983.g013
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alternative inclusion of the last exon. We designed primers specific
for exon 8 of MBOAT7, exon 12 of DNMT3L and exon 23 of
LAMC2 and amplified the cDNAs. qPCR confirmed all AS events
(Figs 11 C,12C and 13C).
In a further experiment, RHPN1 (Rhophilin, Rho GTPase
binding protein 1) showed a higher expression of bleeding exon
15b in DM2 compared to CTR (Fig. 14A, B). Indeed, qPCR
Figure 14. Increased RHPN1 exon 15 bleeding in DM2 patients. A) EAA analysis identified an AS event on exon 15b of RHPN1 mRNA
transcript ENST00000289013. The AS area is enlarged and exon 15b, more frequently included in DM2 patients, is highlighted in solid gray. B) The box
plot shows the increased expression of Affymetrix probe set 3119603 recognizing exon 15b in DM2 patients compared to CTR (n = 10, **** p,
0.0001). Values were normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed
using the specific primer pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2=19, CTR= 15; *** p,0.001).
doi:10.1371/journal.pone.0093983.g014
Figure 15. Increased CFYIP2 exon 1 inclusion in DM2 patients. A) EAA analysis identified an AS event on exon 1 of CFYIP2 mRNA transcript
ENST00000377576. The AS area is enlarged and exon 1, more frequently included in DM2 patients, is highlighted in solid gray. B) The box plot shows
the increased expression of Affymetrix probe set 2837276 recognizing exon 1, in DM2 patients compared to CTR (n = 10, * p,0.05). Values are
normalized for the levels of the whole transcript. The splice index (SI) is indicated. C) Validation qPCR assays were performed using the specific primer
pair indicated as black arrowhead in panel A. Results are shown as fold change (DM2= 19, CTR= 15; ** p,0.01).
doi:10.1371/journal.pone.0093983.g015
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experiments confirmed the more frequent inclusion of exon 15b in
DM2 patients (Fig. 14 C).
Finally, CFYIP (cytoplasmic FMR1 interacting protein 2)
mRNA transcripts presented an alternative transcript start, with
a prominent expression of the shorter isoform in DM2 patients
compared to CTR subjects (Fig. 15 A and B). Again, qPCR assays
using specific primer pairs confirmed this event (Fig. 15 C).
Pathways and Networks of genes with aberrant splicing
events
To gain insight into the molecular pathways involving the
identified aberrantly spliced genes, Interactive Pathway Analysis
(IPA) of experimental data was performed by Ingenuity software.
Using the list of 218 genes involved in AS events predicted by
EAA, IPA identified several pathways and functions that might be
relevant for DM2. Top categories are shown on Tab.1, while the
complete list of significant categories is represented in Tab. S6.
Particularly worth noting are ‘‘Skeletal and Muscular Disorders’’
and ‘‘Neurological Diseases’’ categories among Diseases, ‘‘Cell
Death and Survival’’ and ‘‘Cellular Development’’ among
Molecular and Cellular Functions, ‘‘Calcium signaling’’ among
Pathways and ‘‘Cardiac Arrythmia’’ among Cardiac Toxic
Functions.
Then, using MetaCore integrated software, we analyzed the
networks produced by the list of recognized AS events. It was
analyzed by using the ‘‘Direct interactions algorithm’’, which
creates a network only from the objects under analysis (Fig. S6). In
the core of this network, we could find genes like c-Abl, VCL,
DNA-PK, c-Src, beta-catenin, and WNK. Interestingly the last 4
genes were also found within the DMPK (Dystrophia Myotonica
Protein Kinase) gene network (See Methods) (Fig. S7).
Expanding automatically our dataset using the ‘Analyze
Networks’ algorithm (see Methods), amongst the first enriched
subnetworks, we found one containing CDC42BPB (CDC42
binding protein kinase beta (DMPK-like)) with DNA-PK and
SHP2 in the core (Fig. S8) and another with IDH3 (Isocitrate
DeHydrogenease 3) with respiratory complex III and c-Myc in its
core and containing RHPN1 (Fig. S9). Indeed, when networks for
DM-related genes were built (see Methods) an intersection
Table 1. Most significant categories and functions.
DISEASE AND DISORDERS p-value
Immunological disease 3.11E-04 -2.13E-02
Neurological disease 3.11E-04 -2.30E-02
Skeletal and Muscular Disorders 3.11E-04 -1.77E-02
Cancer 9.22E-04 -2.46E-02
Reproductive System Disease 9.22E-04 -1.77E-02
MOLECULAR AND CELLULAR FUNCTIONS p-value
Cell Death and Survival 1.05E-04 -2.13E-02
Cellular Development 1.81E-04 -1.83E-02
Cell Morphology 2.85E-04 -1.77E-02
Cellular Movement 5.95E-04 -2.46E-02




Epithelial Adherens Junction Signaling 1.62E00
Fatty Acid Biosynthesis Initiation II 1.46E00
Palmitate Biosynthesis I (Animals) 1.46E00
Urea Cycle 1.46E00
Calcium Signaling 1.42E00
TOP CARDIOTOXIC FUNCTIONS p-value
Increased Levels of Albumin 1.77E-02 -1.77E-02
Increased Levels of Alkaline Phosphatase 1.77E-02 -6.12E-01
Cardiac Arrythmia 4.07E-03 -3.25E-01
Tachycardia 4.07E-03 -3.25E-01
Cardiac Dilation 1.77E-02 -1.45E-01
Congenital Heart Anomaly 1.77E-02 -4.35E-01
Cardiac Hypoplasia 3.95E-02 -3.95E-02
doi:10.1371/journal.pone.0093983.t001
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between our dataset was found in the CDC42BPB subnetwork
consisting in CDC42BPB, MRCK and PPRC (not shown).
Discussion
Dysregulation of AS is a fundamental molecular trait of DM2,
affecting many genes involved in muscle homeostasis and function
[18,20–23,25–27,42–44]. Thus, the identification of the AS
alterations is a crucial step for our understanding of the
pathogenetic mechanisms of the disease and for the identification
of biomarkers of functional impairment [27]. However, gaining
insight in the molecular network of the gene expression and AS
alterations triggered by the DM2 genetic lesion is hurdled by the
variability between patients and between different muscles of the
same subject [27]. Another substantial obstacle is constituted by
the fact that DM2 is a rare disease and by the difficulty of
obtaining specimens with intact RNA. The current study validates
many known DM2-affected splice events and further expands its
number. Indeed, we identified in our profiling group 35 AS
alterations previously described in DM1, DM2 or both. In order to
minimize the number of false positives, we adopted very stringent
inclusion criteria. As a consequence, we can postulate the presence
of some false negatives. Accordingly, adopting more inclusive
criteria (with IterPLIER gene and exon level normalization)
several other known AS events were also present in our dataset,
such as SOS1 exon 25 skipping [27], BIN1 exon 11 inclusion [42],
OPA1 exon 4 skipping [27], VEGFA exon 6 inclusion [27],
MBNL2 exon 7 inclusion [27], ALPK3 exon 2 inclusion [27],
PHK1 exon 19 inclusion [27]. Moreover, exon 22 skipping of
ATP2A1 [25] displayed a SI value that was just below threshold,
but was consistently validated by PCR (AP, SG and FM,
unpublished). Finally, certain genes displayed very low or no
detectable signals in our array analysis. Thus, data on well
characterized AS aberrations, such as INSR exon 11 skipping
[20,45] or ClC1 intron 2 inclusion [18,45–47] were inconclusive.
Intriguingly, we also found that exon inclusion AS events were
more common than exon skipping ones. While this may be due to
technical reasons, it is worth noting that a similar trend was also
observed in other studies [21,27,28].
The emerging scenario shows that we still are in a first phase of
data acquisition that needs to be followed by an accurate meta-
analysis in order to dissect out the molecular pathways and the
single genes leading to disease form simple ‘‘bystanders’’. In spite
of this mandatory cautionary note, we can hypothesize that the
identified AS events are likely to be of pathogenetic importance.
Indeed, IPA analysis of pathways and functions involving the
identified genes displayed several relevant top-scoring hits.
Significantly, this analysis indicated that among Diseases, ‘‘Neu-
rological Diseases’’ and ‘‘Skeletal and Muscular Disorders’’ were
the second and the third top categories, respectively.
Furthermore, among relevant gene networks identified there
were those involving IDH3, DMPK and DMPK-like CDC42BPB.
The IDH3isozyme is a heterotetramer mitochondrial enzyme that
is composed of two alpha subunits (IDH3A), one beta subunit
(IDH3B), and one gamma subunit (IDH3G) [48,49]. IDH3B and
G isoforms are both aberrantly spliced in DM2 patients and this
deregulation correlated with the mitochondrial pathways dysfunc-
tion observed in DM2 muscles [50].
The DMPK network is also of obvious relevance, given its role
in DM1 pathogenesis [2–4]. Unlike CTG triple expansion,
DMPK deficiency does not seem to play an essential role in the
pathogenetic mechanism. Accordingly, Dmpk2/2 mice do not
reproduce the complex and multisystemic DM1 phenotype,
suggesting that haploinsufficiency of this gene is not the primary
mechanism of disease. Nevertheless, DMPK inactivation might
contribute to altered ion homeostasis in muscle and heart. [51,52].
Moreover, DMPK promotes myogenic gene expression in skeletal
myoblasts and its disruption may contribute to skeletal muscle
wasting [53]. Thus, our finding indicates that the aberrant splicing
of DMPK network component c-Src, WNK1, DNA-PK, beta-
catenin and TYRP1 may be functionally relevant.
Also interesting is the AS deregulation of CDC42BPB and of
other components of its network, given that CDC42BPB is a
kinase protein that is involved in cytoskeletal reorganization and
actin formation [54].
A subset of identified AS was also validated by PCR in a larger
patient cohort. Our investigation and the one of Nakamori et
al.[27] identified several AS events in the LIMCH1 gene in DM2
and DM1, respectively. Both studies failed to confirm exon 12
skipping both in DM1 [27] and DM2 (this study), underlining the
importance of data validation with an independent technique.
However, we successfully validated exon 11 skipping, confirming
that LIMCH1 is a target of DM2 AS aberrations.
Array analysis also identified a more frequent inclusion of
PDLIM3 exon 4 in DM2 patients and this event was validated by
qPCR. Our data are in agreement with the observations of
Ohsawa and collaborators in DM1 patients [41]. They found that
the isoforms predominant in CTR are PDLIM3a (exon 5/6
inclusion/exon 4 exclusion isoform) and PDLIM3c (exon 5
inclusion and exons 4/6 exclusion isoform), while DM1 muscles
expressed the PDLIM3b isoform (exon 4 inclusion and exons 5/ 6
exclusion isoform). Lin et al. [17] also found in both DM1and
DM2 muscles that PDLIM3 exon 5 was alternatively spliced as
well. However, in our DM2 patient group, EAA data did not
predict significant AS events in exons other than exon 4. Of note,
AS of LIMCH1 exon 4 was also observed in the hippocampus of
Mbnl2 -/- mice, suggesting that this event might under MBNL
control also in human skeletal muscles [55].
The PDLIM3b isoform, with exon 4 inclusion, is mainly
expressed in fetal skeletal muscles, whereas PDLIM3a and
PDLIM3c are predominantly detected after birth [41]. Thus,
the predominant expression of the fetal exon 4 in DM2 muscle is
consistent with the reactivation of a fetal gene program due to the
muscle disease [56,57]. Moreover, PDLIM3 seems to have a role
in muscle differentiation since the knocking down of PDLIM3
affects the expression of myogenin and MyoD [58]. Furthermore,
while PDLIM3a and PDLIM3c are expressed predominantly in
muscle (heart and skeletal muscles), PDLIM3b has a more
ubiquitous expression pattern, suggesting that exon 4 containing
isoforms may have functions other than those executed in skeletal
muscles [41]. It is also worth noting that three aberrantly spliced
genes, PDLIM3, PDLIM5 and LDB3, all belong to the same
family [59],suggesting the impairment of a whole molecular
function.
Another protein family that is affected by DM2 AS disruption is
CAMK2. Indeed, we found that CAMK2B and CAMK2G are
aberrantly spliced in DM2 patients. Accordingly, Nakamori et al.
recently showed that the AS of CAMK2A and CAMK2G is
affected in DM1 too, although for CAMK2G a different AS event
was observed. The aberrant AS of CAMK2 genes are of particular
interest since several studies indicated that Ca2+ signaling is
probably the most deregulated pathway in both DM patients and
mouse models [17,21,22,25,26,44,60,61]. Accordingly, in our IPA
analysis, ‘‘Calcium signaling’’ is among the top affected Pathways.
Moreover, Nakamori et al [27] found that splicing of CAMK2G
was affected also in Mbnl1 knockout mice, suggesting that Mbnl1
sequestration might influence the AS of this gene.
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CAMK2 is a multimeric ubiquitous holoenzyme regulating
many pathways in response to Ca2+ signaling, including
neurotransmitter synthesis and release, cytoskeleton organization
and calcium homeostasis [62–64]. Expressed from 4 CaMK2
genes (A, B, G and D or a, b, c and d), over 20 different types of
CaMK2 have been identified [65,66]. The primary difference
between the CaMK2 isoforms results from a series of inserts
named ‘‘variable regions’’ laying between the Ca2+/CaM-binding
domain and the association domain [64]. These variable regions
modulate substrate specificity, calmodulin regulation, holoenzyme
formation, or subcellular, targeting/localization [67]. Of rele-
vance, the aminoacids encoded by the exons aberrantly spliced in
CAMK2G (exon 18), CAMK2B (exon 16/17) and CAMK2A
(exon 14) all lay in the variable regions [64].
In another study, it has been shown that the presence of variable
region I in CaMKIIG lowered the amount of Ca2+/calmodulin
required for activation [68]. Thus, alterations of the variable
regions of the CAMK2 family may lead to an increased binding
affinity of the protein to the Ca2+/CaM complex that, in turn,
ameliorates the muscle weakness characterizing the disease. On
the other hand, a tighter CAMK2 to CaM interaction may also
perturb the graduation of the responses following repeated Ca2+
spikes in the cytoplasm.
In conclusion, our genome wide analysis provided a database of
aberrant splicing events in the skeletal muscle of DM2 patients.
The affected genes are involved in numerous pathways and
networks important for muscle physio-pathology, suggesting that
the identified variants may contribute to DM2 pathogenesis.
Supporting Information
Figure S1 Increased MBNL1 exon 7 inclusion in DM2 patients.
A) EAA analysis identified an AS event on exon 7 of MBNL1
mRNA transcript. ENST00000282486. The AS area is enlarged
and exon 7, more frequently included in DM2 patients, is
highlighted in solid gray. B) The box plot shows the increased
expression of Affymetrix probe set 2648174 recognizing exon 7, in
DM2 patients compared to CTR (n= 10, **** p,0.0001). Values
are normalized for the levels of the whole transcript. The splice
index (SI) is indicated.
(PPTX)
Figure S2 Increased FHOD1 exon 11 inclusion in DM2
patients. A) EAA analysis identified an AS event on exon 11 of
FHOD1 mRNA transcript ENST00000258201. The AS area is
enlarged and exon 11, more frequently included in DM2 patients,
is highlighted in solid gray. B) The box plot shows the increased
expression of Affymetrix probe set 3695543 recognizing exon 11 in
DM2 patients compared to CTR (n= 10, *** p,0.001). Values
are normalized for the levels of the whole transcript. The splice
index (SI) is indicated.
(PPTX)
Figure S3 Increased LDB3 exon 4 inclusion in DM2 patients. A)
EAA analysis identified an AS event on exon 4 of LDB3 mRNA
transcript ENST00000372056. The AS area is enlarged and exon
4, more frequently included in DM2 patients, is highlighted in
solid gray. B) The box plot shows the increased expression of
Affymetrix probe set 3255989 recognizing exon 4, in DM2
patients compared to CTR (n= 10, **** p,0.0001), as found by
Vihola et al., 2010. Values are normalized for the levels of the
whole transcript. The splice index (SI) is indicated.
(PPTX)
Figure S4 Increased NFIX exon 7 inclusion in DM2 patients. A)
EAA analysis identified an AS event on exon 7 of NFIX mRNA
transcript ENST00000358552. The AS area is enlarged and exon 7,
more frequently included in DM2 patients, is highlighted in solid
gray. B) The box plot shows the increased expression of Affymetrix
probe set 3822162 recognizing exon 7, in DM2 patients compared
to CTR (n= 10, **** p,0.0001). Values are normalized for the
levels of the whole transcript. The splice index (SI) is indicated.
(PPTX)
Figure S5 Increased MAPT exon 6 skipping in DM2 patients.
A) EAA analysis identified an AS event on exon 6 of MAPT
mRNA transcript ENST00000344290. The AS area is enlarged
and exon 6, less frequently included in DM2 patients, is
highlighted in solid gray. B)The box plot shows the decreased
expression of Affymetrix probe set 3723723 recognizing exon 6, in
DM2 patients compared to CTR (n= 10, **** p,0.0001). Values
are normalized for the levels of the whole transcript. The splice
index (SI) is indicated.
(PPTX)
Figure S6 Direct Interactions Network of LIMMA significant
genes. The algorithm created a network consisting only of genes
with significant AS events and no other elements were added to
the network. Only genes with one or more connections are shown.
Up-regulated genes are marked with red circles; down-regulated
with blue circles. Intensity of color corresponds to intensity of fold
change.
(PPTX)
Figure S7 DMPK gene network. Network generated by the
‘Auto Expand’ algorithm around DMPK gene. The algorithm
added genes to the network giving preference to those with more
connectivity to the initial gene and halted when the sub-networks
intersect or the overall size reached a pre-established limit of 50
genes. Genes in our data set, such as b-catenin, c-src, DNA-PK
and WNK1 were found within the network. The genes with
colored circles are those with AS significant events. Up-regulated
genes are marked with red circles; down-regulated with blue
circles. Intensity of color corresponds to intensity of fold change.
(PPTX)
Figure S8 CDC42BP network. Enriched sub network by
‘Analyze Network’ algorithm from LIMMA significant genes
containing CDC42BP (DMPK-like) gene. The genes with colored
circles are those with AS significant events. Up-regulated genes are
marked with red circles; down-regulated with blue circles.
Intensity of color corresponds to intensity of fold change.
(PPTX)
Figure S9 IDH3 network. Enriched sub network by ‘Analyze
Network’ algorithm from LIMMA significant genes containing
IDH3 genes. The genes with colored circles are those with AS
significant events. Up-regulated genes are marked with red circles;
down-regulated with blue circles. Intensity of color corresponds to
intensity of fold change.
(PPTX)
Table S1 Primers sequences.
(XLSX)
Table S2 Clinical characteristics of the patients used for array
profiling.
(XLSX)
Table S3 AS events predicted by EAA analysis.
(XLSX)
Table S4 Previously described DM-AS events predicted by EAA
analysis.
(XLSX)
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Table S5 Clinical characteristics of the patients used for PCR
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Table S6 Complete enrichment analysis report.
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